Tesamorelin in Australia: legal status and listed suppliers

Legal status in Australia

Prescription only. Tesamorelin is not listed by name in the Poisons Standard (June 2026), but Schedule 4 lists growth hormone releasing hormones (GHRHs) as a class, and tesamorelin is a GHRH analogue. No ARTG registration was found.

As understood at 2026-09-22. Verify with the TGA.

What Tesamorelin is

Tesamorelin is a synthetic, stabilised analogue of growth hormone-releasing hormone, the hypothalamic hormone that prompts the pituitary to release growth hormone. Unlike most substances covered on this site it is an approved medicine in the United States, sold as Egrifta, for one specific indication.

Full Tesamorelin page: targets and research →

Listed suppliers in Australia

6 of the 10 suppliers we list in Australia list Tesamorelin. Listed, not endorsed: each row is the supplier’s own stated terms.

Au Peptide Labs Australia For laboratory research use only. Not for human consumption. Aussie Peptides Australia Research use only. Statements have not been evaluated by the TGA. We do not ship internationally at this time. Australian Peptide Site Australia Intended for laboratory and scientific research use only. Global Peptides Australia Unmodified peptides are sold for research use only. Next Gen Peptides Australia Not for human consumption. Synapse Peptides Australia Australia All products are supplied strictly for research purposes only and are not intended for human or veterinary use.

Clinical Research

Effects of Tesamorelin, a Growth Hormone-Releasing Factor, in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension

Falutz J, Potvin D, Mamputu JC, et al. (2010). JAIDS Journal of Acquired Immune Deficiency Syndromes. human 404 people with HIV on antiretroviral therapy with excess abdominal fat, randomised, double-blind, 12 months

Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Clinical Trial

Stanley TL, Feldpausch MN, Oh J, et al. (2014). JAMA. human 50 people with HIV on antiretroviral therapy with abdominal fat accumulation, randomised, double-blind, placebo-controlled, 6 months

Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial

Clemmons DR, Miller S, Mamputu JC (2017). PLOS ONE. human 53 people with type 2 diabetes, randomised to placebo or one of two tesamorelin groups, 12 weeks

Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity

Ellis RJ, Vaida F, Hu K, et al. (2025). The Journal of Infectious Diseases. human 73 people with HIV, virally suppressed, with abdominal obesity; phase 2, randomised, open-label against standard of care, 6 months